Nothing Special   »   [go: up one dir, main page]

TR201900097T4 - Anti̇psi̇koti̇k i̇le i̇ndüklenen ki̇lo artişini tedavi̇ etmeye yöneli̇k yöntemler. - Google Patents

Anti̇psi̇koti̇k i̇le i̇ndüklenen ki̇lo artişini tedavi̇ etmeye yöneli̇k yöntemler. Download PDF

Info

Publication number
TR201900097T4
TR201900097T4 TR2019/00097T TR201900097T TR201900097T4 TR 201900097 T4 TR201900097 T4 TR 201900097T4 TR 2019/00097 T TR2019/00097 T TR 2019/00097T TR 201900097 T TR201900097 T TR 201900097T TR 201900097 T4 TR201900097 T4 TR 201900097T4
Authority
TR
Turkey
Prior art keywords
induced weight
antipsycotic
treatment
methods
reducing
Prior art date
Application number
TR2019/00097T
Other languages
English (en)
Turkish (tr)
Inventor
Deaver Daniel
Todtenkopf Mark
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of TR201900097T4 publication Critical patent/TR201900097T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TR2019/00097T 2010-08-23 2011-08-23 Anti̇psi̇koti̇k i̇le i̇ndüklenen ki̇lo artişini tedavi̇ etmeye yöneli̇k yöntemler. TR201900097T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37612010P 2010-08-23 2010-08-23

Publications (1)

Publication Number Publication Date
TR201900097T4 true TR201900097T4 (tr) 2019-02-21

Family

ID=45723770

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00097T TR201900097T4 (tr) 2010-08-23 2011-08-23 Anti̇psi̇koti̇k i̇le i̇ndüklenen ki̇lo artişini tedavi̇ etmeye yöneli̇k yöntemler.

Country Status (19)

Country Link
US (11) US8778960B2 (hu)
EP (3) EP2608670B1 (hu)
JP (1) JP5684388B2 (hu)
AU (4) AU2011293502B2 (hu)
CA (1) CA2807965C (hu)
CY (1) CY1121128T1 (hu)
DK (2) DK2608670T3 (hu)
ES (2) ES2969625T3 (hu)
FI (1) FI3446565T3 (hu)
HR (2) HRP20240109T1 (hu)
HU (2) HUE065427T2 (hu)
LT (2) LT3446565T (hu)
NZ (1) NZ606730A (hu)
PL (2) PL2608670T3 (hu)
PT (2) PT3446565T (hu)
RS (2) RS58312B1 (hu)
SI (2) SI2608670T1 (hu)
TR (1) TR201900097T4 (hu)
WO (1) WO2012027359A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2445502T (lt) * 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
ES2729679T3 (es) 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
HUE065427T2 (hu) 2010-08-23 2024-05-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által indukált súlygyarapodás kezelésére
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
US20210220298A1 (en) * 2018-06-29 2021-07-22 Tufts Medical Center, Inc. Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
WO2023105103A1 (es) 2022-06-17 2023-06-15 Mesoestetic Pharma Group, S.L Composición cosmética sinérgica despigmentante de la piel

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874217A (en) 1958-10-30 1961-08-02 Albert Boehringer Normorphine derivatives
GB981046A (en) 1962-07-02 1965-01-20 British Drug Houses Ltd Hexahydro-4ah-8,9c-iminoethano phenanthro-[4,5-b,c,d]-furan derivatives
BE634402A (fr) 1962-07-02 1964-01-02 British Drug Houses Ltd Dérivés de l'hydrophénanthrène et leurs procédés de préparation
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH581624A5 (hu) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (de) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
DE3220831A1 (de) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
JPH05231100A (ja) 1992-02-25 1993-09-07 Hazama Gumi Ltd トンネル用通気仕切り
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP0729353B2 (en) 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JP2000503019A (ja) 1996-01-10 2000-03-14 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ 複素環縮合モルフィノイド誘導体（ｉｉ）
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
JP4890710B2 (ja) 1999-08-13 2012-03-07 サザン・リサーチ・インスティテュート ピリドモルフィナン類、チエノモルフィナン類及びそれらの使用
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
ES2278647T3 (es) 1999-11-29 2007-08-16 Adolor Corporation Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides.
EP1353909B1 (en) 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
DE60320770D1 (de) 2002-03-20 2008-06-19 Euro Celtique Sa Verfahren zur verabreichung von buprenorphin zur behandlung von depression
ES2249722T3 (es) 2002-05-30 2006-04-01 Eli Lilly And Company Antagonistas de receptor de opioides.
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
AU2003281060A1 (en) 2002-07-16 2004-02-02 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
AU2003298691A1 (en) 2002-11-18 2004-06-15 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
PL1617832T3 (pl) * 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
CA2553309A1 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7244866B2 (en) 2004-05-14 2007-07-17 Janssen Pharmaceutical N.V. Carboxamido opioid compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
PL2251330T3 (pl) * 2004-11-05 2012-12-31 Rensselaer Polytech Inst 4-hydroksybenzomorfany
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2615774C (en) 2005-07-21 2014-12-09 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
EP1983991A2 (en) 2006-02-01 2008-10-29 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
JP2010504325A (ja) 2006-09-20 2010-02-12 マリンクロット インコーポレイテッド 置換モルフィナン−６−オン、並びにその塩および中間体の調製
EP2073636B1 (en) 2006-10-17 2012-09-05 Penick Corporation Process for preparing oxymorphone
WO2008070462A2 (en) 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
EP2134330B1 (en) 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
EP2148864A2 (en) 2007-05-16 2010-02-03 Rensselaer Polytechnic Institute Fused-ring heterocycle opioids
WO2009009083A1 (en) 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
WO2009023567A1 (en) 2007-08-09 2009-02-19 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
TR201809734T4 (tr) 2008-02-14 2018-07-23 Alkermes Inc Seçici opioid bileşikler.
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
ES2534055T3 (es) 2008-07-21 2015-04-16 Rensselaer Polytechnic Institute Opioides de amina no fenólicos con sustituyentes de gran tamaño
AU2009342654B2 (en) 2009-03-19 2013-09-05 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
ES2729679T3 (es) 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
WO2012018872A1 (en) 2010-08-04 2012-02-09 Mallinckrodt Llc N-demethylation of 6-keto morphinans
HUE065427T2 (hu) 2010-08-23 2024-05-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által indukált súlygyarapodás kezelésére
EP2655332B1 (en) 2010-12-23 2016-07-13 Phoenix Pharmalabs, Inc. Novel morphinans useful as analgesics
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
PL3153171T3 (pl) 2011-12-15 2019-02-28 Alkermes Pharma Ireland Limited Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms

Also Published As

Publication number Publication date
US20120077800A1 (en) 2012-03-29
AU2018202410A1 (en) 2018-04-26
EP2608670A1 (en) 2013-07-03
EP4306164A3 (en) 2024-03-20
WO2012027359A1 (en) 2012-03-01
AU2018202410B2 (en) 2019-02-28
HUE041981T2 (hu) 2019-06-28
DK3446565T3 (da) 2024-01-22
RS65091B1 (sr) 2024-02-29
EP4306164A2 (en) 2024-01-17
US20240293394A1 (en) 2024-09-05
US20140349999A1 (en) 2014-11-27
US11793805B2 (en) 2023-10-24
PL3446565T3 (pl) 2024-04-02
EP3446565B1 (en) 2023-11-01
US8778960B2 (en) 2014-07-15
US20180271855A1 (en) 2018-09-27
HRP20190169T1 (hr) 2019-03-22
CA2807965A1 (en) 2012-03-01
JP2013536239A (ja) 2013-09-19
US11185541B2 (en) 2021-11-30
JP5684388B2 (ja) 2015-03-11
AU2011293502B2 (en) 2015-03-19
SI3446565T1 (sl) 2024-03-29
US11351166B2 (en) 2022-06-07
US20190307742A1 (en) 2019-10-10
US10716785B2 (en) 2020-07-21
AU2015201907B2 (en) 2016-12-22
HUE065427T2 (hu) 2024-05-28
US9943514B2 (en) 2018-04-17
CY1121128T1 (el) 2019-12-11
US9517235B2 (en) 2016-12-13
EP3446565A1 (en) 2019-02-27
PL2608670T3 (pl) 2019-05-31
NZ606730A (en) 2015-05-29
AU2011293502A1 (en) 2013-02-28
AU2015201907A1 (en) 2015-05-07
US20220280502A1 (en) 2022-09-08
DK2608670T3 (en) 2019-02-11
LT2608670T (lt) 2019-01-25
AU2017200396A1 (en) 2017-02-09
US20170119757A1 (en) 2017-05-04
PT3446565T (pt) 2024-01-29
US20210038594A1 (en) 2021-02-11
US20210015812A1 (en) 2021-01-21
US20210046065A1 (en) 2021-02-18
AU2017200396B2 (en) 2018-04-19
US9126977B2 (en) 2015-09-08
US20160051538A1 (en) 2016-02-25
RS58312B1 (sr) 2019-03-29
EP2608670B1 (en) 2018-10-31
US11241425B2 (en) 2022-02-08
SI2608670T1 (sl) 2019-04-30
HRP20240109T1 (hr) 2024-03-29
ES2705726T3 (es) 2019-03-26
LT3446565T (lt) 2024-01-10
US10300054B2 (en) 2019-05-28
PT2608670T (pt) 2019-02-01
FI3446565T3 (fi) 2024-01-30
ES2969625T3 (es) 2024-05-21
CA2807965C (en) 2016-03-15
EP2608670A4 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
TR201900097T4 (tr) Anti̇psi̇koti̇k i̇le i̇ndüklenen ki̇lo artişini tedavi̇ etmeye yöneli̇k yöntemler.
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
PH12014502577A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
EA201201657A1 (ru) Лечение диабета
IN2012DN02463A (hu)
UA107827C2 (en) Antibody cd40
EA201301018A1 (ru) Режимы дозирования для лечения болезни фабри
MX2019010602A (es) Inhibidores de cdk.
UA115231C2 (uk) Сполуки імідазопіролідинонів
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
UA107666C2 (uk) Застосування l-серину як лікарського засобу для попередження та/або лікування свербіжу шкіри
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
EA201201670A1 (ru) Циклический амин-азагетероциклический карбоксамид
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
EP2588121A4 (en) C5A ANALOGUES AND METHODS OF USE THEREOF
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями